$480,000 of EXACT SCIENCES lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Support legislative efforts to develop alternative diagnostics legislation in lieu of LDT rule. Support veteran access to guideline-recommended colorectal cancer screening. HR 842/S 339 support Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act: This bill allows, beginning in 2028, for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Coverage is limited to those under a certain age (age 68 in 2028, increased by one year every year thereafter) and to one test every 11 months."
You can find more data on corporate lobbying on Quiver Quantitative.
EXAS Insider Trading Activity
EXAS insiders have traded $EXAS stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EXAS stock by insiders over the last 6 months:
- KATHERINE S ZANOTTI sold 3,207 shares for an estimated $170,612
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EXAS Hedge Fund Activity
We have seen 242 institutional investors add shares of EXAS stock to their portfolio, and 294 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 6,970,041 shares (+33.6%) to their portfolio in Q1 2025, for an estimated $301,733,074
- JPMORGAN CHASE & CO removed 2,989,522 shares (-85.6%) from their portfolio in Q1 2025, for an estimated $129,416,407
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 2,009,503 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $86,991,384
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,707,287 shares (+120.1%) to their portfolio in Q1 2025, for an estimated $73,908,454
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,350,794 shares (-31.6%) from their portfolio in Q1 2025, for an estimated $58,475,872
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 1,195,473 shares (-34.7%) from their portfolio in Q1 2025, for an estimated $51,752,026
- MILLENNIUM MANAGEMENT LLC removed 886,022 shares (-37.5%) from their portfolio in Q1 2025, for an estimated $38,355,892
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EXAS Analyst Ratings
Wall Street analysts have issued reports on $EXAS in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 06/24/2025
- Evercore ISI Group issued a "Outperform" rating on 05/02/2025
- Baird issued a "Outperform" rating on 05/02/2025
- Guggenheim issued a "Buy" rating on 04/11/2025
- Mizuho issued a "Outperform" rating on 04/10/2025
- Piper Sandler issued a "Overweight" rating on 02/26/2025
- Scotiabank issued a "Sector Outperform" rating on 02/24/2025
To track analyst ratings and price targets for EXAS, check out Quiver Quantitative's $EXAS forecast page.
EXAS Price Targets
Multiple analysts have issued price targets for $EXAS recently. We have seen 9 analysts offer price targets for $EXAS in the last 6 months, with a median target of $65.0.
Here are some recent targets:
- Vijay Kumar from Evercore ISI Group set a target price of $68.0 on 07/08/2025
- Luke Sergott from Barclays set a target price of $65.0 on 06/24/2025
- Gerard Cassidy from RBC Capital set a target price of $54.0 on 05/02/2025
- Catherine Schulte from Baird set a target price of $72.0 on 05/02/2025
- Subbu Nambi from Guggenheim set a target price of $60.0 on 04/11/2025
- Anthony Petrone from Mizuho set a target price of $60.0 on 04/10/2025
- David Westenberg from Piper Sandler set a target price of $70.0 on 02/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
